TargED Biopharmaceuticals Launches Phase 1 Trial for Innovative Stroke Treatment TargED Biopharmaceuticals has initiated a Phase 1 clinical trial for TGD001, aimed at revolutionizing thrombotic disease treatments and addressing acute ischemic stroke.

TargED Biopharmaceuticals Launches Phase 1 Trial for Innovative Stroke Treatment #Netherlands #Utrecht #TargED #TGD001 #thrombolytics